INFU vs PATH · P/E 25, rev $134.9M vs P/E 19, rev $1.61B
InfuSystems Holdings Inc (INFU) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
InfuSystems Holdings Inc (INFU) is a medical devices company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported INFU revenue for 2024-12-31 was $134.9M. Net income was $2.3M. Revenue was up 7.2% from 2023-12-31 to 2024-12-31. INFU currently screens at market cap $186.5M and trailing P/E 25.0.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
INFU currently screens at market cap $186.5M and trailing P/E 25.0. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the INFU and PATH stock pages for the full models.
Not investment advice.